Article
New Xarelto (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Prog
Rating:
0.0
Views:
126
Likes:
1
Library:
1
Data includes several analyses from the landmark VOYAGER PAD trial, including findings in high-risk patients with critical limb ischemia (CLI) after lower-extremity revascularization (LER) XARELTO® has the potential to be the first anticoagulant in 20 years to show a benefit in patients with PAD after LER[i] The comprehensive PAD program within EXPLORER continues to generate new findings that may shift the way symptomatic and chronic patients are managed
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value